%0 Journal Article
%T Effect of 4£¿years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program£¿ registry
%A Peter A Lee
%A Judith Ross
%A John A Germak
%A Robert Gut
%J International Journal of Pediatric Endocrinology
%D 2012
%I BioMed Central
%R 10.1186/1687-9856-2012-15
%X The American Norditropin Studies: Web-Enabled Research (ANSWER) Program£¿, a US-based registry, collects long-term efficacy and safety information on patients treated with Norditropin£¿ (somatropin rDNA origin, Novo Nordisk A/S) at the discretion of participating physicians. A total of 120 children (90 boys, 30 girls) with NS, na£¿ve to previous GH treatment, were included in this analysis.The mean (SD) baseline age of subjects (n£¿=£¿120) was 9.2 (3.8) years. Mean (SD) HSDS increased from ¨C2.65 (0.73) at baseline to ¨C1.32 (1.11) at Y4 (n£¿=£¿17). Subjects showed continued increase in HSDS from baseline to Y4 without significant differences between genders at Y1 or Y2. The mean (SD) GH dose was 47 (11) mcg/kg/day at baseline and 59 (16) mcg/kg/day at Y4. There was a negative correlation between baseline age and ¦¤HSDS at Y1 (R£¿=£¿¨C0.3156; P£¿=£¿0.0055) and Y2 (R£¿=£¿¨C0.3394; P£¿=£¿0.017). ¦¤HSDS at Y1 was significantly correlated with ¦¤HSDS at Y2 (n£¿=£¿37; R£¿=£¿0.8527, P£¿<£¿0.0001) and Y3 (n£¿=£¿20; R£¿=£¿0.5145; P£¿=£¿0.0203), but not Y4 (n£¿=£¿12; R£¿=£¿0.4066, P£¿=£¿0.1896).GH treatment-na£¿ve patients with NS showed continued increases in HSDS during 4£¿years of treatment with GH with no significant differences between genders up to 2£¿years. Baseline age was negatively correlated with ¦¤HSDS at Y1 and Y2. Whether long-term therapy in NS results in continued increase in HSDS to adult height remains to be investigated.ClinicalTrials.gov NCT01009905
%K Growth hormone
%K Noonan Syndrome
%K Somatropin
%K Short stature
%K Body height
%K Treatment outcome
%U http://www.ijpeonline.com/content/2012/1/15/abstract